Salah Uddin Khan1, Benjamin D Anderson2, Gary L Heil1, Song Liang1, Gregory C Gray3. 1. Department of Environmental and Global Health, College of Public Health and Health Professions Emerging Pathogens Institute, University of Florida, Gainesville. 2. Department of Environmental and Global Health, College of Public Health and Health Professions Emerging Pathogens Institute, University of Florida, Gainesville Division of Infectious Diseases, Global Health Institute, & Nicholas School of the Environment, Duke University, Durham, North Carolina Laboratory of One Health Research, Program in Emerging Infectious Diseases, Duke-NUS Graduate Medical School, Singapore. 3. Division of Infectious Diseases, Global Health Institute, & Nicholas School of the Environment, Duke University, Durham, North Carolina Laboratory of One Health Research, Program in Emerging Infectious Diseases, Duke-NUS Graduate Medical School, Singapore.
Abstract
INTRODUCTION: Given that influenza A(H9N2) is recognized as a pandemic threat, we evaluated the overall burden of influenza A(H9N2) infections among avian-exposed human populations. METHODS: We performed a systematic search of PubMed, AGRICOLA, and CAB Abstracts databases for literature published during 1997-2013. Studies reporting serological evidence of human influenza A(H9N2) infection among avian-exposed populations were included. We used a World Health Organization (WHO)-recommended case definition for serological evidence of infection based on results of hemagglutination inhibition (HI) and microneutralization (MN) assays. We calculated overall seroprevalence through a random effects meta-analysis model. RESULTS: Seroprevalence data reported by the studies ranged from 1% to 43% (median, 9%) by HI, which was not significantly different from the seroprevalence estimated through the WHO-recommended case definition (median, 1.3%; range, 0.5%-42.6%). Reported seroprevalence by MN ranged from 0.6% to 9% (median, 2.7%), which was greater than the seroprevalence estimated through the WHO-recommended case definition (median, 0.3%; range, 0.1%-1.4%). CONCLUSIONS: A small proportion of avian-exposed humans had evidence of influenza A(H9N2) infection. As the virus has a near global distribution in poultry, it seems likely that present surveillance efforts are missing mild or asymptomatic infections among avian-exposed persons. It seems prudent to closely monitor avian-exposed populations for influenza A(H9N2) infection to provide prepandemic warnings.
INTRODUCTION: Given that influenza A(H9N2) is recognized as a pandemic threat, we evaluated the overall burden of influenza A(H9N2) infections among avian-exposed human populations. METHODS: We performed a systematic search of PubMed, AGRICOLA, and CAB Abstracts databases for literature published during 1997-2013. Studies reporting serological evidence of humaninfluenza A(H9N2) infection among avian-exposed populations were included. We used a World Health Organization (WHO)-recommended case definition for serological evidence of infection based on results of hemagglutination inhibition (HI) and microneutralization (MN) assays. We calculated overall seroprevalence through a random effects meta-analysis model. RESULTS: Seroprevalence data reported by the studies ranged from 1% to 43% (median, 9%) by HI, which was not significantly different from the seroprevalence estimated through the WHO-recommended case definition (median, 1.3%; range, 0.5%-42.6%). Reported seroprevalence by MN ranged from 0.6% to 9% (median, 2.7%), which was greater than the seroprevalence estimated through the WHO-recommended case definition (median, 0.3%; range, 0.1%-1.4%). CONCLUSIONS: A small proportion of avian-exposed humans had evidence of influenza A(H9N2) infection. As the virus has a near global distribution in poultry, it seems likely that present surveillance efforts are missing mild or asymptomatic infections among avian-exposed persons. It seems prudent to closely monitor avian-exposed populations for influenza A(H9N2) infection to provide prepandemic warnings.
Authors: Benjawan P Khuntirat; In-Kyu Yoon; Patrick J Blair; Whitney S Krueger; Malinee Chittaganpitch; Shannon D Putnam; Krongkaew Supawat; Robert V Gibbons; Sirima Pattamadilok; Pathom Sawanpanyalert; Gary L Heil; John A Friary; Ana W Capuano; Gregory C Gray Journal: Clin Infect Dis Date: 2011-10 Impact factor: 9.079
Authors: Y Chen; Q Zheng; K Yang; F Zeng; S-Y Lau; W L Wu; S Huang; J Zhang; H Chen; N Xia Journal: Clin Microbiol Infect Date: 2011-07-13 Impact factor: 8.067
Authors: Vincent C C Cheng; Jasper F W Chan; X Wen; W L Wu; T L Que; H Chen; K H Chan; K Y Yuen Journal: J Infect Date: 2011-02-26 Impact factor: 6.072
Authors: Philippe Buchy; Sirenda Vong; Simon Chu; Jean-Michel Garcia; Tran Tinh Hien; Vo Minh Hien; Mey Channa; Do Quang Ha; Nguyen Van Vinh Chau; Cameron Simmons; Jeremy J Farrar; Malik Peiris; Menno D de Jong Journal: PLoS One Date: 2010-05-27 Impact factor: 3.240
Authors: Timothy J Powell; Annette Fox; Yanchun Peng; Le Thi Quynh Mai; Vu T K Lien; Nguyen L K Hang; Lili Wang; Laurel Y-H Lee; Cameron P Simmons; Andrew J McMichael; Jeremy J Farrar; Brigitte A Askonas; Tran Nhu Duong; Pham Quang Thai; Nguyen Thi Thu Yen; Sarah L Rowland-Jones; Nguyen Tran Hien; Peter Horby; Tao Dong Journal: J Infect Dis Date: 2011-11-11 Impact factor: 5.226
Authors: Shailesh D Pawar; Babasaheb V Tandale; Chandrashekhar G Raut; Saurabh S Parkhi; Tanaji D Barde; Yogesh K Gurav; Sadhana S Kode; Akhilesh C Mishra Journal: PLoS One Date: 2012-05-18 Impact factor: 3.240
Authors: Mary Zacour; Brian J Ward; Angela Brewer; Patrick Tang; Guy Boivin; Yan Li; Michelle Warhuus; Shelly A McNeil; Jason J LeBlanc; Todd F Hatchette Journal: Clin Vaccine Immunol Date: 2016-01-27
Authors: Mahmoud M Naguib; Reiner Ulrich; Elisa Kasbohm; Christine L P Eng; Donata Hoffmann; Christian Grund; Martin Beer; Timm C Harder Journal: J Virol Date: 2017-11-14 Impact factor: 5.103
Authors: Jose L Sanchez; Michael J Cooper; Christopher A Myers; James F Cummings; Kelly G Vest; Kevin L Russell; Joyce L Sanchez; Michelle J Hiser; Charlotte A Gaydos Journal: Clin Microbiol Rev Date: 2015-07 Impact factor: 26.132
Authors: Gudrun S Freidl; Henk-Jan van den Ham; Maciej F Boni; Erwin de Bruin; Marion P G Koopmans Journal: Sci Rep Date: 2016-02-08 Impact factor: 4.379
Authors: Jie Zhou; Jie Wu; Xianqiao Zeng; Guofeng Huang; Lirong Zou; Yingchao Song; Divya Gopinath; Xin Zhang; Min Kang; Jinyan Lin; Benjamin J Cowling; William G Lindsley; Changwen Ke; Joseph Sriyal Malik Peiris; Hui-Ling Yen Journal: Euro Surveill Date: 2016-09-01